Processa Pharmaceuticals Prices $7 Million Public Offering

Published on 06/17/2025 at 12:49

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals, Inc. - Special Call	Jul. 09
Processa Pharmaceuticals, Inc. Terminates the Licensing Agreement Between Ocuphire Pharma, Inc	Jul. 01	CI
Processa Pharmaceuticals, Inc. Provides Updates on its Product Pipeline	Jul. 01	CI
Processa Pharmaceuticals Prices $7 Million Public Offering	Jun. 17	MT
Processa Pharmaceuticals Grants Intact Therapeutics Exclusive Option to License Gastroparesis Drug Candidate; Shares Rise	Jun. 17	MT
Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate	Jun. 17	CI
Processa Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 08	CI
Processa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	Mar. 20	CI
Processa Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	Mar. 19	CI
Processa Pharmaceuticals Inc - On Feb 4, Received Nasdaq Notice For Bid Price Non-Compliance	Feb. 10	RE
Processa Pharmaceuticals, Inc. Provides Updates on its Product Pipeline	24-10-30	CI
Processa Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	24-10-30	CI
Processa Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer	24-10-02	CI
Processa Pharmaceuticals, Inc. Announces Positive Preclinical Data for NGC-IRI	24-08-19	CI
Processa Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-08-13	CI
Top Midday Gainers	24-07-30	MT
Processa Pharmaceuticals, Inc. Announces FDA Clearance of IND Application for A Phase 2 Clinical Trial of NGC-Cap in Breast Cancer	24-07-30	CI
Processa Pharmaceuticals Appoints Russell Skibsted as CFO	24-07-17	MT
Processa Pharmaceuticals, Inc. Announces CFO Changes	24-07-17	CI
Processa Pharmaceuticals, Inc. Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1B Dose-Escalating Trial with Ngc-Cap in Gastrointestinal Cancer	24-06-11	CI
Top Premarket Decliners	24-06-07	MT
Processa Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	24-05-10	CI
Processa Pharmaceuticals, Inc. Names Steven Cha as Senior Vice President of Clinical Research	24-04-30	CI
Certain Common Warrants of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024.	24-04-29	CI
Certain Restricted Stock Units of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024.	24-04-29	CI